Combination of RET siRNA and irinotecan inhibited the growth of medullary thyroid carcinoma TT cells and xenografts via apoptosis

Cancer Science

Volumn 101, Issue 4, 2010, Pages 941-947

  Koga, Kimiko ^a   Hattori, Yoshiyuki ^a   Komori, Mihoko ^a   Narishima, Ryota ^b   Yamasaki, Masahiro ^b   Hakoshima, Motoki ^a   Fukui, Tetsuya ^b   Maitani, Yoshie ^a  

^a Institute of Medicinal Chemistry   (Japan)

^b HOSHI UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 HYDROXYCAMPTOTHECIN; CALCITONIN; CASPASE 3; CASPASE 7; IRINOTECAN; PROTEIN BCL 2; SMALL INTERFERING RNA; ANTINEOPLASTIC AGENT; CAMPTOTHECIN; DRUG DERIVATIVE; PROTEIN RET; RET PROTEIN, HUMAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CALCITONIN BLOOD LEVEL; CELL PROLIFERATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DOWN REGULATION; DRUG SENSITIVITY; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE THERAPY; MONOTHERAPY; MOUSE; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; REARRANGED DURING TRANSFECTION ONCOGENE; THYROID MEDULLARY CARCINOMA; TUMOR XENOGRAFT; ANIMAL; CELL CYCLE; DRUG EFFECT; DRUG SCREENING; GENETICS; HUMAN; INSTITUTE FOR CANCER RESEARCH MOUSE; MEDULLARY CARCINOMA; METABOLISM; NUDE MOUSE; PATHOLOGY; PROTO ONCOGENE; THYROID TUMOR; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; CAMPTOTHECIN; CARCINOMA, MEDULLARY; CASPASE 3; CELL CYCLE; CELL LINE, TUMOR; CELL PROLIFERATION; DOWN-REGULATION; FEMALE; HUMANS; MICE; MICE, INBRED ICR; MICE, NUDE; PROTO-ONCOGENE PROTEINS C-RET; PROTO-ONCOGENES; RNA, SMALL INTERFERING; THYROID NEOPLASMS; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77956114179     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2009.01484.x     Document Type: Article

References (33)

1. Kodama Y, Asai N, Kawai K et al. The RET proto-oncogene: a molecular therapeutic target in thyroid cancer. Cancer Sci 2005; 96: 143-8.
2. Moley JF. Medullary thyroid carcinoma. Curr Treat Options Oncol 2003; 4: 339-47.
3. Hansford JR, Mulligan LM. Multiple endocrine neoplasia type 2 and RET: from neoplasia to neurogenesis. J Med Genet 2000; 37: 817-27.
4. Treanor JJ, Goodman L, de SF et al. Characterization of a multicomponent receptor for GDNF. Nature 1996; 382: 80-3.
5. Santoro M, Melillo RM, Carlomagno F, Vecchio G, Fusco A. Minireview: RET: normal and abnormal functions. Endocrinology 2004; 145: 5448-51.
6. Cohen MS, Moley JF. Surgical treatment of medullary thyroid carcinoma. J Intern Med 2003; 253: 616-26.
7. Gimm O. Thyroid cancer. Cancer Lett 2001; 163: 143-56.
8. Jones RL, Judson IR. The development and application of imatinib. Expert Opin Drug Saf 2005; 4: 183-91.
9. de Groot JW, Zonnenberg BA, van Ufford-Mannesse PQ et al. A phase II trial of imatinib therapy for metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 2007; 92: 3466-9.
10. Strock CJ, Park JI, Rosen DM et al. Activity of irinotecan and the tyrosine kinase inhibitor CEP-751 in medullary thyroid cancer. J Clin Endocrinol Metab 2006; 91: 79-84.
11. Drosten M, Frilling A, Stiewe T, Putzer BM. A new therapeutic approach in medullary thyroid cancer treatment: inhibition of oncogenic RET signaling by adenoviral vector-mediated expression of a dominant-negative RET mutant. Surgery 2002; 132: 991-7.
12. Drosten M, Stiewe T, Putzer BM. Antitumor capacity of a dominant-negative RET proto-oncogene mutant in a medullary thyroid carcinoma model. Hum Gene Ther 2003; 14: 971-82.
13. Parthasarathy R, Cote GJ, Gagel RF. Hammerhead ribozyme-mediated inactivation of mutant RET in medullary thyroid carcinoma. Cancer Res 1999; 59: 3911-4.
14. Messina M, Robinson BG. Technology insight: gene therapy and its potential role in the treatment of medullary thyroid carcinoma. Nat Clin Pract Endocrinol Metab 2007; 3: 290-301.
15. Pai SI, Lin YY, Macaes B, Meneshian A, Hung CF, Wu TC. Prospects of RNA interference therapy for cancer. Gene Ther 2006; 13: 464-77.
16. Marsh DJ, Theodosopoulos G, Martin-Schulte K et al. Genome-wide copy number imbalances identified in familial and sporadic medullary thyroid carcinoma. J Clin Endocrinol Metab 2003; 88: 1866-72.
17. Hattori Y, Yoshizawa T, Koga K, Maitani Y. NaCl induced high cationic hydroxyethylated cholesterol-based nanoparticle-mediated synthetic small interfering RNA transfer into prostate carcinoma PC-3 cells. Biol Pharm Bull 2008; 31: 2294-301.
18. Hattori Y, Fukushima M, Maitani Y. Non-viral delivery of the connexin 43 gene with histone deacetylase inhibitor to human nasopharyngeal tumor cells enhances gene expression and inhibits in vivo tumor growth. Int J Oncol 2007; 30: 1427-39.
19. Yoshizawa T, Hattori Y, Hakoshima M, Koga K, Maitani Y. Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts. Eur J Pharm Biopharm 2008; 70: 718-25.
20. Hattori Y, Koga K, Izumisawa T et al. The distribution of mRNA expression and protein after hydrodynamic injection of transgene in mice. Biol Pharm Bull 2009; 32: 755-9.
21. Drosten M, Hilken G, Bockmann M et al. Role of MEN2A-derived RET in maintenance and proliferation of medullary thyroid carcinoma. J Natl Cancer Inst 2004; 96: 1231-9.
22. Kaczirek K, Schindl M, Weinhausel A et al. Cytotoxic activity of camptothecin and paclitaxel in newly established continuous human medullary thyroid carcinoma cell lines. J Clin Endocrinol Metab 2004; 89: 2397-401.
23. Moley JF, Wells SA, Dilley WG, Tisell LE. Reoperation for recurrent or persistent medullary thyroid cancer. Surgery 1993; 114: 1090-5.
24. Tisell LE, Dilley WG, Wells SA Jr. Progression of postoperative residual medullary thyroid carcinoma as monitored by plasma calcitonin levels. Surgery 1996; 119: 34-9.
25. de MH, Bertrand JR, Fusco A et al. siRNA nanoformulation against the ret/PTC1 junction oncogene is efficient in an in vivo model of papillary thyroid carcinoma. Nucleic Acids Res 2008; 36: e2.
26. Barone MV, Sepe L, Melillo RM et al. RET/PTC1 oncogene signaling in PC Cl 3 thyroid cells requires the small GTP-binding protein Rho. Oncogene 2001; 20: 6973-82.
27. Ji Y, Hayashi K, Amoh Y et al. The camptothecin derivative CPT-11 inhibits angiogenesis in a dual-color imageable orthotopic metastatic nude mouse model of human colon cancer. Anticancer Res 2007; 27: 713-8.
28. Koizumi F, Kanzawa F, Ueda Y et al. Synergistic interaction between the EGFR tyrosine kinase inhibitor gefitinib ("Iressa") and the DNA topoisomerase I inhibitor CPT-11 (irinotecan) in human colorectal cancer cells. Int J Cancer 2004; 108: 464-72.
29. Shao RG, Cao CX, Shimizu T, O'Connor PM, Kohn KW, Pommier Y. Abrogation of an S-phase checkpoint and potentiation of camptothecin cytotoxicity by 7-hydroxystaurosporine (UCN-01) in human cancer cell lines, possibly influenced by p53 function. Cancer Res 1997; 57: 4029-35.
30. Wang HG, Reed JC. Mechanisms of Bcl-2 protein function. Histol Histopathol 1998; 13: 521-30.
31. Hinze R, Gimm O, Taubert H et al. Regulation of proliferation and apoptosis in sporadic and hereditary medullary thyroid carcinomas and their putative precursor lesions. Virchows Arch 2000; 437: 256-63.
32. Ludwig L, Kessler H, Wagner M et al. Nuclear factor-kappaB is constitutively active in C-cell carcinoma and required for RET-induced transformation. Cancer Res 2001; 61: 4526-35.
33. Segouffin-Cariou C, Billaud M. Transforming ability of MEN2A-RET requires activation of the phosphatidylinositol 3-kinase/AKT signaling pathway. J Biol Chem 2000; 275: 3568-76.